Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Non-Inferiority Studies May (Bio)Creep Out Of Limelight After GAO Report

Executive Summary

A report on FDA's use of non-inferiority trials by the Government Accountability Office could in fact signal the end of the political wrangling over the study method
Advertisement

Related Content

FDA’s Guidance Document To-Do List
FDA’s Guidance Document To-Do List
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
Restanza Superiority Trials Intended To Avoid Non-Inferiority "Quagmire"
Gilead Prices Cystic Fibrosis Drug Cayston At Slight Premium To Competitor
Advanced Life Sciences Restanza Blocked By New FDA Efficacy Criteria
FDA Safety Decisions On Ketek To Get Formal Review By House Committee

Topics

Advertisement
UsernamePublicRestriction

Register

PS052585

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel